Metastatic Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors
Key Points
Key Points
- The focus of this guideline is advanced or metastatic well-differentiated G1-G3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including tumors arising in sites such as the pancreas, stomach, small intestine, colon, rectum, and appendix.
- These are classified according to mitotic rate or Ki-67 index (a measure of the percentage of primary tumor cells that are dividing).
- This guideline focuses on strategies for controlling the growth of these tumors.
Treatment
...Treatment...
...I. G...
...ation 1.1Selection of initial treatment opti...
...commendation 1.2All treatment decisions s...
...dation 1.3Patients should be assess...
...II. System...
...First-line Sy...
...ndation 2.1SSAs (octreotide or lanreo...
...ation 2.2In the less common circumstance of...
...Second- or L...
...mendation 2.3Peptide receptor radionuclide t...
...ommendation 2.4Everolimus is recommended fo...
...III. Systemic Th...
...Fir...
....1SSAs (octreotide or lanreotide) are recommen...
...mmendation 3.2Chemotherapy (e.g., capecitabine an...
...dation 3.3Chemotherapy (e.g., CAPTEM), everolimu...
...commendation 3.4PRRT for SSTR-positive tum...
...IV. Systemic...
...on 4.1The range of systemic options o...
Table 1. WHO Classification and Grading Criteria...
...Systemic Therapy for Tumor Control i...
...ieves that cancer clinical trials are vital...